2024 NICE 技术鉴定指南:司利弗明用于治疗复发或难治性B细胞急性淋巴细胞白血病的25 岁及以下患者[TA975]

2024-05-15 英国国家卫生与临床优化研究所 NICE官网 发表于上海

司利弗明治疗25岁及以下复发或难治性b细胞急性淋巴细胞白血病的循证建议。

中文标题:

2024 NICE 技术鉴定指南:司利弗明用于治疗复发或难治性B细胞急性淋巴细胞白血病的25 岁及以下患者[TA975]

英文标题:

Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under

发布日期:

2024-05-15

简要介绍:

司利弗明治疗25岁及以下复发或难治性b细胞急性淋巴细胞白血病的循证建议。

相关资料下载:
[AttachmentFileName(sort=1, fileName=tisagenlecleucel-for-treating-relapsed-or-refractory-bcell-acute-lymphoblast.pdf)] GetToolGuiderByIdResponse(projectId=1, id=602e31c003ea30d3, title=2024 NICE 技术鉴定指南:司利弗明用于治疗复发或难治性B细胞急性淋巴细胞白血病的25 岁及以下患者[TA975], enTitle=Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under, guiderFrom=NICE官网, authorId=0, author=, summary=司利弗明治疗25岁及以下复发或难治性b细胞急性淋巴细胞白血病的循证建议。, cover=https://img.medsci.cn/20240514/1715671200049_5579292.jpg, journalId=0, articlesId=null, associationId=85, associationName=英国国家卫生与临床优化研究所, associationIntro=英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence)是NHS的组织,设在伦敦和曼彻斯特。NICE成立于1999年4月1日,目标是确保每个英格兰和威尔士人平等享有NHS医疗的机会。NICE制定指南,设定质量标准,管理国家数据库,为NHS、当地权威部门和其他组织提供指南。, copyright=0, guiderPublishedTime=Wed May 15 00:00:00 CST 2024, originalUrl=, linkOutUrl=, content=<p>司利弗明治疗25岁及以下复发或难治性b细胞急性淋巴细胞白血病的循证建议。</p>, tagList=[TagDto(tagId=463503, tagName=司利弗明)], categoryList=[CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100)], articleKeywordId=463503, articleKeyword=司利弗明, articleKeywordNum=6, guiderKeywordId=463503, guiderKeyword=司利弗明, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=1249, appHits=3, showAppHits=0, pcHits=22, showPcHits=1246, likes=0, shares=0, comments=0, approvalStatus=1, publishedTime=Thu May 16 18:36:00 CST 2024, publishedTimeString=2024-05-15, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=dajiong, createdTime=Wed May 15 10:13:27 CST 2024, updatedBy=8538692, updatedName=梅斯话题小助手, updatedTime=Wed May 15 19:20:52 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=上海, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=tisagenlecleucel-for-treating-relapsed-or-refractory-bcell-acute-lymphoblast.pdf)])
tisagenlecleucel-for-treating-relapsed-or-refractory-bcell-acute-lymphoblast.pdf
下载请点击:
评论区 (0)
#插入话题